BioStock Studio: Immunicum’s CEO on the company’s new therapeutic focus

Swedish immunotherapy company Immunicum has broadened its cancer treatment focus with the addition of drug candidate DCP-001 thanks to the merger with Dutch biotech DCprime. Treating tumour recurrence is now a top priority for the company, and Immunicum’s CEO Erik Manting came by the BioStock Studio to talk more in depth about this new focus and how the addition of DCP-001 impacts Immunicum’s business strategy.

Watch the interview with Erik Manting at

This is a press release from BioStock - Connecting Innovation & Capital.


Documents & Links